Dasiglucagon in severe hypoglycemia: a profile of its use

Subcutaneous dasiglucagon (Zegalogue®), a next generation glucagon analog, is convenient and valuable addition to ready-to-use formulations for the rescue treatment of severe hypoglycemia in patients aged ? 6 years with diabetes. A single dose reverses insulin-induced typically within 10 min this population, without need additional intervention. The drug generally well tolerated, nausea vomiting being most frequent adverse reactions. overall safety profile consistent that expected treatment. Dasiglucagon available auto-injector prefilled syringe forms can be carried at room temperature. Glucagon emergency kits are standard option hypoglycemia, potential serious complication diabetes They require mixing powder sterile water before administration; step may cause errors delay an situation. Thus, have been developed. approved USA min, intervention, tolerated. hypoglycemia.